Drug Combination Details
| General Information of the Combination (ID: C28720) | |||||
|---|---|---|---|---|---|
| Name | Epigallocatechin gallate NP Info | + | TNF-related apoptosis inducing ligand Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Prostate cancer
[ICD-11: 2C82]
|
Investigative | [1] | ||
|
Brain cancer
[ICD-11: 2A00]
|
Investigative | [2] | |||
|
Pancreatic cancer
[ICD-11: 2C10]
|
Investigative | [3] | |||
|
Melanoma
[ICD-11: 2C30]
|
Investigative | [4] | |||
|
Colon cancer
[ICD-11: 2B90]
|
Investigative | [5] | |||
|
Nasopharyngeal cancer
[ICD-11: 2B6B]
|
Investigative | [6] | |||
| Click to Show/Hide the Whole Disease Information of This Combination | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ANGPT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BAD | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BIRC3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CASP6 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CASP8 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MMP-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MMP-3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MMP-9 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | PRAP1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TIMP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | LNCaP | CVCL_0395 | Prostate carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. | |||||
| Experiment 2 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | MIA PaCa-2 | CVCL_0428 | Pancreatic ductal adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Combination of epigallocatechin-3-gallate and TRAIL synergistically increase the apoptosis and cleavage of procaspase-3 in pancreatic cancer cells. | |||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [6] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Activity | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Activity | CASP8 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Activity | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CFLAR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | FADD | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | CNE-1 | CVCL_6888 | Human nasopharyngeal carcinoma | Homo sapiens | ||
| CNE-2 | CVCL_6889 | Human nasopharyngeal carcinoma | Homo sapiens | |||
| C666-1 | CVCL_7949 | Nasopharyngeal carcinoma | Homo sapiens | |||
| NP69SV40T | CVCL_F755 | Healthy | Homo sapiens | |||
| Experimental
Result(s) |
EGCG sensitizes human nasopharyngeal carcinoma cells to TRAIL-mediated apoptosis by activation NF-kappaB. | |||||
| Experiment 2 Reporting the Effect of This Combination | [4] | |||||
| Molecule(s)
Regulation |
Up-regulation | Activity | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | TRAIL-R1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-375 | CVCL_0132 | Amelanotic melanoma | Homo sapiens | ||
| Experimental
Result(s) |
EGCG enhances TRAIL-mediated apoptosis in human melanoma A375 cell line. | |||||
| Experiment 3 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | PEA15 | Molecule Info | ||
| In-vitro Model | U-87MG ATCC | CVCL_0022 | Glioblastoma | Homo sapiens | ||
| A-172 | CVCL_0131 | Glioblastoma | Homo sapiens | |||
| U-251MG | CVCL_0021 | Astrocytoma | Homo sapiens | |||
| Experimental
Result(s) |
Epigalocatechin-3-gallate (EGCG) downregulates PEA15 and thereby augments TRAIL-mediated apoptosis in malignant glioma. | |||||
| Experiment 4 Reporting the Effect of This Combination | [5] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Activation of autophagic flux by epigallocatechin gallate mitigates TRAIL-induced tumor cell apoptosis via down-regulation of death receptors. | |||||
